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Abstract: The development of new anti-cancer drugs of algal origin represents 
one of the least explored frontiers in medicinal chemistry. In this regard, the 
diversity of micro- and macroalgae found in Brazilian coastal waters can be 
viewed as a largely untapped natural resource. In this report, we describe a 
comparative study on the cytotoxic properties of extracts obtained from the 
Laurencia complex: Laurencia aldingensis, L. catarinensis, L. dendroidea, L. 
intricata, L. translucida, L. sp, and Palisada flagellifera. All of these species 
were collected in the coastal waters of the State of Espírito Santo, Brazil. Four 
out of the twelve samples initially investigated were found to show significant 
levels of toxicity towards a model tumor cell line (human uterine sarcoma, 
MES-SA). The highest levels of cytotoxicity were typically associated with 
non-polar (hexane) algal extracts, while the lowest levels of cytotoxicity were 
found with the corresponding polar (methanol) extracts. In this report, we 
also describe a biological model currently in development that will not only 
facilitate the search for new anti-cancer drug candidates of algal origin, but 
also permit the identification of compounds capable of inducing the destruction 
of multi-drug resistant tumors with greater efficiency than the pharmaceuticals 
currently in clinical use.  
Keywords:
macroalgae
Laurencia complex
anti-cancer activity
MES-SA
MES-SA/Dx5
Hela
Introduction
 Out of the more than 25,000 known species 
of algae, only about fi fteen are currently grown on a 
large-scale for biotechnological applications (Raja et 
al., 2008). Algae are considered to be a largely untapped 
natural resource and investigations involving them are 
one of the least explored frontiers of biotechnology and 
natural products chemistry (Pinto et al. 2000; Cardozo 
et al., 2007; Chakabourty et al., 2009). Signifi cant 
advances in the discovery and development of new anti-
cancer drugs of algal origin have been recently reported 
in the literature. Newly identifi ed algal drug candidates 
include representatives of the terpene, steroid, and 
polyketide families (Mayer & Gustafson, 2008). Drug-
induced over-expression of the multi-drug effl ux pump 
P-glycoprotein (P-gp) is thought to be one of the leading 
causes of chemotherapy failure in clinical oncology 
(Higgins, 2007; Dawson & Locker, 2006; Lage, 2008; 
Perez-Thomas, 2006). Because P-gp can remove many 
unrelated chemotherapeutic agents from the target 
cells, including agents to which the tumor had not been 
previously exposed (Higgins, 2007; Dawson & Locker, 
2006), these cells are referred to as multi-drug resistant 
(MDR) mutants. 
 One of the most gratifying fi ndings that can arise 
from any drug screening program is the identifi cation of 
new drug candidates that are capable of eliminating MDR 
tumor cells more effi ciently than the drugs currently in 
clinical use. The discovery of new, more benign inhibitors 
of such drug effl ux pumps can also be facilitated by 
the biological model currently in development in our 
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laboratories.
 In this report, we describe our initial results on 
the search for novel anti-cancer agents in marine algae 
found on the coast of the Brazilian State of Espírito 
Santo. We also outline a biological model currently in 
development to guide our screening efforts. This model 
aids in the identification of potential new anti-cancer 
candidates and, at the same time, of those that should be 
less susceptible to the action of promiscuous therapy-
induced drug-efflux pumps such as P-gp. 
Materials and Methods
Reagents and cell culture media 
 McCoy’s 5A modified medium, Dulbecco’s 
modified Eagle’s medium (DMEM), doxorubicin 
hydrochloride, fungizone (amphotericin B), penicillin, 
streptomycin, thiazolyl blue tetrazolium bromide (MTT), 
ethylenediamine tetraacetic acid (EDTA; disodium salt), 
trypsin, and Trypan Blue were obtained from Sigma-
Aldrich (St. Louis, USA). Fetal bovine serum (FBS) 
from Vitrocell Embriolife (Campinas, Brazil). NaCl from 
Synth (Diadema, Brazil), sodium bicarbonate from Merck 
(Darmstadt, Germany), D-glucose from Becto Chemical 
(São Paulo, Brazil), KCl from Cetus (São Paulo, Brazil), 
Dulbecco’s phosphate buffered saline (DPBS) from 
Gibco BRL (Grand Island, USA), and dimethylsulfoxide 
(DMSO) from Vetec Química Fina Ltda. (Duque de 
Caxias, Brazil) were all of high-purity grade and used 
as received. Water was distilled, deionized and filtered 
prior to use (Millipore Milli-Q system; resistivity, 18 MΩ 
cm).
Instruments and methods
 Stock solutions of doxorubicin were prepared in 
water and their respective concentrations determined by 
absorption spectroscopy on a Shimadzu (Kyoto, Japan) 
Model UV-1650 PC spectrophotometer employing a 
molar extinction coefficient of 11,500 M-1 cm-1 at 480 nm 
(Zeman et al., 1998).
 Algal extracts were prepared via initial 
sonication (30 min) of approximately 30 g of the 
respective powdered and dried biomass with 300 mL 
of hexane. After standing overnight, the mixture was 
filtered and the solid mass subjected to two more cycles 
of extraction with hexane. The hexane-extracted biomass 
was then further processed by performing three extraction 
cycles with chloroform followed by three cycles of 
methanol extraction. The solvent was evaporated from 
the filtrates on a rotary evaporator to obtain three distinct 
classes of algal extracts, namely the hexane extract, the 
chloroform extract, and the methanol extract. In selected 
experiments, we extracted the original algal dry powder 
sample only with methanol; these extracts are referred 
to here as “crude” methanol extracts. Stock solutions of 
the final algal extracts were prepared in either DMSO 
or ethanol and subsequently diluted in the cell growth 
media in order to maintain the final concentration of 
organic solvent in the medium below 0.5% (by volume). 
The species of algae investigated are listed in Table 1. 
Table 1. Species of Laurencia complex seaweed investigated 
in this study. Voucher specimens were deposited in the 
Herbarium Maria Eneida P. Kauffman Fidalgo at the Instituto 
de Botânica, São Paulo, SP, Brazil.
Algae species Collect information Voucher number
Laurencia aldingensis 
Saito & Womersley
ES, Anchieta, Ponta dos 
Castelhanos 01/07/2007 SP 399.933
Laurencia catarinensis 
Cord-Mar & M.T. Fujii
ES, Anchieta, Ponta dos 
Castelhanos 01/07/2007 SP 400.209
Laurencia dendroidea J. 
Agardh
ES, Anchieta, Praia de 
Parati 30/06/2007 SP 400.198
Laurencia intricata J.V. 
Lamour
ES, Guarapari, Praia de 
Meaípe 04/06/2008 SP 400.793
Laurencia sp. ES, Anchieta, Ilhote de 
Ubu 04/06/2008 SP 399.936
Laurencia translucida 
M.T. Fujii & Cord-Mar
ES, Anchieta, Praia de 
Parati 30/06/2007 SP 400.213
Palisada flagellifera (J. 
Agardh) K.W. Nam
ES, Anchieta, Ponta dos 
Castelhanos 03/06/2008 SP 400.203
 The trypan blue dye exclusion assay (Perry et 
al., 1997) was routinely employed to assess the quality of 
our original cell cultures; in all experiments performed 
with cell cultures, cell viability was at least 95%. All 
experiments were carried out with cells in the exponential 
growth phase. Cell viability assays were carried out using 
the MTT assay (Mosmann, 1983; Garcia-Peres et al., 
2010). For this purpose, 96-well flat-bottomed microtiter 
plates were seeded at a cell density of 5,000 cells per 
well (100 µL of growth medium per well) and the cells 
allowed to attach and grow for 24 h. The sub-culturing 
protocols used in this study were always in accord with 
the respective ATCC recommendations. The cells were 
subsequently exposed to growth medium containing either 
the standard drug (doxorubicin) or the algal extracts for a 
period of time that typically varied from 24 to 72 h prior 
to MTT analysis. The MTT assays were performed on a 
Model Infinite M200 multi-well plate reader from Tecan 
(Männedorf, Switzerland). Cells exposed to the growth 
medium alone or to the growth medium plus the drug/
extract vehicle (DMSO or ethanol) served as the controls. 
Under our experimental conditions, no significant 
cytotoxicity was observed for the vehicle (organic solvent 
used to prepare the stock solutions). Cell mortality was 
expressed as the viability of cells treated with the drug or 
extract relative to that of the corresponding controls.
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Cell Lines 
 The MES-SA human uterine sarcoma cell line 
(ATCC CRL-1976™) and the corresponding doxorubicin-
resistant mutant (MES-SA/Dx5, ATCC CRL-1977™) 
were obtained from the American Type Culture 
Collection (ATCC; Manassas, VA). These cells were 
grown in modified McCoy’s 5A medium supplemented 
with 10% FBS, amphotericin B (0.63 µg/mL), penicillin 
(100 units/mL) and streptomycin (100 µg/mL). The 
medium used to grow the MES-SA/Dx5 mutants also 
contained doxorubicin (0.5 µM), as required for the 
maintenance of the drug-resistance phenotype (Harker, 
1983; Harker & Sikic, 1985; Larroque-Lombard et al., 
2010). HeLa (CCL-2™) human cervix adenocarcinoma 
cells were kindly provided by Dr. Mari Cleide Sogayar 
(Departamento de Bioquímica, Universidade de São 
Paulo) and grown in DMEM medium, supplemented 
as described above for the McCoy’s medium used to 
grow the MES-SA cells. Cells were grown at 37 oC in a 
humidified atmosphere of 5% CO2 in air. 
Results and Discussion
 In this initial screening, we explored the 
extent to which the chemical agents extracted from 
a variety of Laurencia complex seaweed species 
exhibited cytotoxicity effects toward our primary 
model tumor cell line (MES-SA). For this purpose, we 
initially exposed cultures of MES-SA cells to mixtures 
containing substantial amounts of the algal extracts 
(i.e., 500 µg of algal extract/mL of cell culture media), 
subsequently measuring the cell survival rates after 24 
h of continuous exposure to the extract. Table 2 shows 
that substantial cytotoxicity was associated with some, 
but not all, of these algal extracts. The methanol extracts 
obtained by our sequential extraction protocol (i.e., 
hexane/chloroform/methanol) showed the lowest levels 
of toxicity, even lower than that of the crude methanol 
extracts obtained via direct methanol extraction of the 
original algae dry powder samples. The somewhat higher 
toxicity of the crude methanol extracts relative to the 
sequential methanol extracts is presumably the result of 
the presence of less polar chemical entities in the former 
that are absent in the latter extract because of removal 
during the prior extractions with the less polar solvents. 
Indeed, the hexane extracts of Laurencia catarinensis 
Cord.-Mar. & M.T. Fujii, L. dendroidea J. Agardh, and L. 
translucida M.T. Fujii & Cord.-Mar all show high levels 
of cytotoxicity. Likewise, the chloroform extract of L. 
dendroidea also exhibits a high degree of cytotoxicity, 
but the corresponding extract of L. aldingensis does not 
(Table 2).
Table 2. Relative cytotoxic effects of algal extracts toward 
MES-SA cells. 
Algae species Extracts Relative toxicicity
L. aldingensis chloroform -
L. aldingensis methanol -
L. catarinensis hexane ++
L. catarinensis methanol - -
L. dendroidea hexane ++
L. dendroidea chloroform ++
L. dendroidea methanol -
L. intricata methanol -
L. translucida hexane ++
L. translucida methanol - -
L. sp methanol (crude)* +
P. flagellifera methanol (crude)* +
Key: (++) ≥ 80% cell mortality; (+) 50-79% cell mortality; (-) 30-50% 
cell mortality; (--) <30% cell mortality. Cells were incubated for 24 h 
in the presence of algal extracts (500 µg/mL of growth medium).* See 
Materials and Methods.
 The overall trends observed in Table 2 
were further confirmed by a subsequent experiment 
employing the highly cytotoxic hexane extracts of 
L. dendroidea and L. translucida and the methanol 
extract of L. translucida. In this second study, MES-SA 
cells were exposed for 72 h to variable concentrations 
of the extracts and cell viability again measured by 
the MTT assay. Figure 1 confirms that the methanol 
extract of L. translucida is virtually non-toxic, while 
the corresponding hexane extract of the same alga is 
highly toxic, with an apparent IC50 of about 16 µg/
mL. The IC50 associated with the hexane extract of 
L. dendroidea was ca. 5-fold higher (i.e., 91 µg/mL) 
than that of the hexane extract of L. translucida. For 
comparative purposes, an analogous experiment carried 
out with doxorubicin (a classical and potent anti-cancer 
drug) gave an ID50 of 0.05 µM (i.e., 0.03 µg/mL) for 
MES-SA cells (Figure 2). 
 The use of MES-SA cells for this screening was 
motivated in part by the fact that these cells grow quickly 
(doubling time of ca. 24 h), show desirable morphology, 
are large enough to facilitate counting/analysis of 
drug-induced mechanisms of damage via microscopic 
analysis, are highly susceptible to a large variety of anti-
cancer drugs (i.e., relatively easy to perform in vitro 
assays of mortality), and are also easy to manipulate and 
maintain (Larroque-Lombard, 2010; Lacerda et al., 2005; 
Belostotsky et al., 2011). The susceptibility of MES-SA 
cells to doxorubicin is analogous to that observed for HeLa 
cells (compare panels A and B in Figure 2). HeLa cells 
have been extensively used in pre-clinical studies and, 
for this reason, the inclusion of this cell line in selected 
screening experiments may facilitate the comparison of the 
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potency associated with putative new drug candidates with 
that of previous candidates studied with HeLa cells. On 
the other hand, the MES-SA line has a feature that is quite 
attractive in terms of the development of novel screening 
protocols: the existence of a commercially-available MES-
SA mutant (namely the MES-SA/Dx5 line) that is also 
easy to work with and maintain and shows the classical 
multi-drug resistance phenotype (i.e., over-expression of 
the drug efflux pump, P-gp). Therefore, the inclusion of 
this mutant cell line in any screening protocol permits the 
identification not only of novel anti-cancer agents capable 
of inducing the mortality of MDR tumor cells, but also 
of novel inhibitors of P-gp. For comparative purposes, the 
ID50 for doxorubicin was 0.05 µM for the wild type cell 
line (MES-SA), but almost two orders of magnitude higher 
(i.e., 3.4 µM; see Figure 2, panel A) for the MDR mutant 
(MES-SA/Dx5). Analogous differences in the response 
of these cell lines to doxorubicin have been reported by 
others authors (Larroque-Lombard et al., 2010).
Conclusions
 Our initial studies indicate that four of the 
twelve extracts of the Laurencia complex seaweeds 
currently under investigation exhibit significant 
cytotoxicity towards MES-SA cells. We are cautiously 
optimistic with respect to these preliminary findings 
and further investigations designed to isolate and identify 
Figure 1. Cytotoxic effects of algal extracts toward human uterine sarcoma (MES-SA) cells. From the top, at 100 µg extract/ml 
of growth medium: Lt-ME, methanol extract of Laurencia translucida; Ld-HE, hexane extract of Laurencia dendroidea; Lt-
HE, hexane extract of Laurencia translucida. The cell cultures were incubated for 72 h in the presence of the algal extracts.
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Figure 2. Cytotoxic effects of doxorubicin on the three tumor cell lines. Panel A: human uterine sarcoma (MES-SA) and its 
corresponding multi-drug resistant mutant (MES-SA/Dx5). Panel B: human cervix adenocarcinoma (HeLa) cells.
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novel and potent anti-cancer drug candidates from these 
extracts are already in progress. The biological model 
under development here is currently being used for a 
wider systematic screening of algal species present in 
waters along the Brazilian seashore. This should expand 
our knowledge of the presence of cytotoxic compounds in 
Brazilian algal species and may identify novel candidate 
compounds for the more effective treatment of multi-
drug resistant tumors (Higgins, 2007; Dawson & Locker, 
2006; Lage, 2008; Perez-Tomas, 2006). In addition, we 
envision that our biological model should also facilitate 
the search for novel chemical inhibitors of P-gp that 
show positive synergism with classical anti-cancer drugs. 
Thus, any enhancement in MES-SA/Dx5 cell mortality 
(e.g., at ID20) in the presence of doxorubicin plus a non-
toxic extract relative to that of doxorubicin alone would 
suggest the possible presence of P-gp inhibitors or other 
agents (e.g., pro-apoptotic factors) in the extract. Hence, 
in our future screening studies, even algal extracts that do 
not show cytotoxic properties will be tested for synergy 
with the standard drug doxorubicin. 
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